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Abstract
Background: The alarming rise in the obesity epidemic and growing concern for the pathologic consequences of the
metabolic syndrome warrant great need for development of obesity-related pharmacotherapeutics. The search for such
therapeutics is severely limited by the slow throughput of animal models of obesity. Amenable to placement into a 96
well plate, zebrafish larvae have emerged as one of the highest throughput vertebrate model organisms for performing
small molecule screens. A method for visually identifying non-toxic molecular effectors of fat metabolism using a live
transparent vertebrate was developed. Given that increased levels of nicotinamide adenine dinucleotide (NAD) via
deletion of CD38 have been shown to prevent high fat diet induced obesity in mice in a SIRT-1 dependent fashion we
explored the possibility of directly applying NAD to zebrafish.
Methods:  Zebrafish larvae were incubated with daily refreshing of nile red containing media starting from a
developmental stage of equivalent fat content among siblings (3 days post-fertilization, dpf) and continuing with daily
refreshing until 7 dpf.
Results: PPAR activators, beta-adrenergic agonists, SIRT-1 activators, and nicotinic acid treatment all caused predicted
changes in fat, cholesterol, and gene expression consistent with a high degree of evolutionary conservation of fat
metabolism signal transduction extending from man to zebrafish larvae. All changes in fat content were visually
quantifiable in a relative fashion using live zebrafish larvae nile red fluorescence microscopy. Resveratrol treatment
caused the greatest and most consistent loss of fat content. The resveratrol tetramer Vaticanol B caused loss of fat
equivalent in potency to resveratrol alone. Significantly, the direct administration of NAD decreased fat content in
zebrafish. Results from knockdown of a zebrafish G-PCR ortholog previously determined to decrease fat content in C.
elegans support that future GPR142 antagonists may be effective non-toxic anti-obesity therapeutics.
Conclusion: Owing to the apparently high level of evolutionary conservation of signal transduction pathways regulating
lipid metabolism, the zebrafish can be useful for identifying non-toxic small molecules or pharmacological target gene
products for developing molecular therapeutics for treating clinical obesity. Our results support the promising potential
in applying NAD or resveratrol where the underlying target protein likely involves Sirtuin family member proteins.
Furthermore data supports future studies focused on determining whether there is a high concentration window for
resveratrol that is effective and non-toxic in high fat obesity murine models.
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Background
Obesity has been increasing in every state in the nation [1]
and has reached an all time high in children [2]. Due to
the adverse health affects of obesity the total cost for med-
ical care and disability associated with obesity was esti-
mated to be 99.2 billion dollars in 1995 [3]. Currently
there are only two pharmaceutical drugs used for the treat-
ment of obesity and these drugs have not been demon-
strated to result in weight loss beyond 5 years [4]. Much
more successful results have been obtained by performing
bariatric surgery, however there are significant risks asso-
ciated with these procedures. The isolation of a small mol-
ecule that can activate lipolysis could have therapeutic
potential for the treatment of obesity. By extension there
is a great need to identify which genes regulate fat metab-
olism to identify potential mechanisms of targeted molec-
ular medicine.
Several monogenic obesity genes have been cloned in
mice including leptin, leptin receptor, carboxypeptidase,
melanocortin-4 receptor, and the orexigenic agouti pro-
tein (for a review see [5]). Mutations in melanocortin-4
receptor have been observed more than any other mono-
genic obesity disease at 1–6% of the surveyed obese pop-
ulation. A variety of other genes have been shown to be
associated with the obesity phenotype including: UCP1-3,
PPARγ, and several adrenergic receptors. A proline to
alanine at position 12 of PPARγ has clearly been shown to
have effects on lipid metabolism. The number of genes
expected to be involved in obesity remains to be deter-
mined.
The zebrafish model organism Danio rerio is currently the
simplest model organism complete with the full comple-
ment of vertebrate organs that can be used in forward
genetic screens. ENU mutagenesis screens have been per-
formed to isolate mutant zebrafish with defects in their
temperature maintenance in an attempt to identify genes
potentially involved in regulating lipid metabolism [6].
This was based in part on the observation that mice miss-
ing the leptin protein or receptor have problems regulat-
ing their temperature. However, to date no one has
completed a forward chemical mutagenesis screen to
result in the identification of genes regulating fat metabo-
lism using zebrafish.
The yolk sac is maternally derived and represents the sole
source of energy for the embryo and larva during early
zebrafish development. Significantly, the yolk sac is a
quantifiably finite source of energy that is largely con-
sumed during the first week of larval development. These
characteristics give the yolk sac distinct advantages for
assaying changes in organismal lipid metabolism.
Methods
Materials
Zebrafish were obtained from the Zebrafish International
Resource Center. All small molecules were obtained from
Sigma chemicals.
Maintenance of Zebrafish
Adult and embryonic zebrafish were maintained accord-
ing to protocols described in The Zebrafish Book [7].
Measurement of Total Fatty Acids and Cholesterol
Pools of 30 to 50 healthy 3 dpf larvae were selected for
daily incubations with fresh E3 media containing small
molecules until 7 dpf before they were clarified by centrif-
ugation at 11,000 rcf for 3 min. Supernatant was removed
and larvae were frozen for chemical analysis. The pool of
larvae was subjected to saponification, conversion to
methyl esters, and extraction with hexane. A known mass
of heptadecanoic acid was added to the larvae pool before
saponification. The methyl esters were quantified by gas
chromatography and the mass was calculated from the
ratio of the area of methyl heptadecanoate to those of
other methyl esters. The conditions for the gas chromato-
graph have been described previously [8]. For cholesterol
measurements at least 30 zebrafish were treated with 1
mM of nicotinic acid or nicotinamide from 3 to 10 dpf
before extraction and quantitation of total cholesterol [9].
Transcript Quantitation by Q-RT-PCR
Twenty 6 dpf zebrafish larvae were exposed to molecules
for 11 hr and flash frozen with liquid nitrogen. RNA was
quickly isolated using Qiagen RNeasy mammalian tissue
protocol, incorporating Qiashredder. RNA levels were
quantified using Nanodrop spectrophotometer and
cDNA was synthesized using equivalent amounts of RNA
using Superscript II Reverse Transcriptase (Invitrogen).
cDNA was quantitated in triplicate by real-time PCR.
Primers pairs used were for GPR109a (also known as
HM74a, TTTCGACGCTCCCATTCTGGATGA and
AGGACGAACTCGCTGAACAGAACA for 60 bp) CD36,
AGATGGTTCCTCTTTCCACCCGTT and ACAGGCAG-
CAAGTACCGATACACA for 144 bp), FABP4 (TGAGCAG-
GGCGTCATCACTATGAA and
TTGTGGTCTTTCCTTCCCAGGTCT for 176 bp), and these
were normalized to PP1A, AGAATTTCAGGCAGTTGT-
GCACGG and TGTGGTTTGTGAAGTCACCTCCCT Qia-
gen Hot Start DNA Polymerase was used for PCR: 15 m
95°C, 45 × (25 s 94°C, 25 s 60°C, 25 s 68°C), and hold
10°C. All reaction single product sizes were first verified
by visualization on agarose gels and melting curve analy-
sis. Fluorescein was included in the reaction to provide a
stable fluorescence baseline. Data was collected with the
Bio-Rad iCycler iQ system using SYBR green to detect
amplicon production. Analysis was performed by the
comparative Ct method so both treated and untreatedNutrition & Metabolism 2008, 5:23 http://www.nutritionandmetabolism.com/content/5/1/23
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samples were normalized to housekeeping gene product
peptidyl-prolyl isomerase A (PPIA) as an internal control.
Hypoxic stress to Zebrafish larvae
Multi-well 48 well plates with 0.5 mL of zebrafish embryo
(E3; [7]) were preconditioned to anoxic conditions by
placement into a Bio-Bag type A environmental chamber
(Becton Dickinson) as described previously [10]. Using a
plate containing at least 20 of 6 dpf zebrafish, the water
was removed and replaced with preconditioned hypoxic
E3 before initiating a second Bio-Bag type A environmen-
tal chamber reaction. Zebrafish were visually monitored
for lack of response to shaking stimuli. After approxi-
mately 2 hours, zebrafish were harvested by rapidly
removing solution and flash freezing in tubes with liquid
nitrogen for Q-RT-PCR analysis.
Small Molecule Treatments with Nile Red and 
Fluorescence Microscopy
Embryos were raised in embryo 3 media (E3: 5 mM NaCl,
0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4, 10E-5
methylene blue) supplemented with 200 μM PTU [7].
Starting at 3 days post-fertilization (dpf), 30 to 50 healthy
larvae were placed into 48 well plates containing E3 with
10 mM Tris pH 7.4 and 10 ng/mL nile red at a density of
10 larvae per well. Nile red was dissolved in 50,000 ×
stock solution at 500 μg/mL in acetone. In order to quan-
titatively prepare the nile red incubation solution 10 μL of
stock solution was first carefully pipetted into 50 mL E3
media to prepare a 10× solution. This was diluted to a
final working concentration of 10 ng/mL. Incubating lar-
vae at higher levels of nile red produced a bright signal
throughout the larvae. Incubation times ranged from 6
hours to overnight to allow for the nile red to equilibrate
and penetrate into the depths of the yolk sac and central
nervous system of 7 dpf larvae as monitored by fluores-
cent microscopy. Incubations were performed without
shaking at 28°C. Media was replaced daily until 7 dpf by
transferring larvae to plates containing solutions pre-
heated to 28°C using baskets. To first determine the work-
ing concentration, groups of 3 dpf zebrafish were exposed
to a ten-fold serial dilution of small molecules and
allowed to develop. Ten-fold sub-lethal dose of molecules
was chosen as the working concentrations for experi-
ments. Molecules were refreshed on a daily basis starting
at 3 dpf. Media was supplemented with 100 μM nicotinic
acid, 100 μM nicotinamide, 50 μM resveratrol (10 mM
stock dissolved in DMSO), or 50 μM resveratrol with 100
μM norepinephrine. At 7 dpf larvae were examined by flu-
orescence microscopy. Nile red was visualized on a Zeiss
Axioplan microscope using a Texas Red filter. Camera
exposure time was established using untreated larva for
signal normalization. Larvae to be compared were placed
in a single depression slide so that the media and depth
were consistent.
Morpholino Injection
At least 30 embryos were injected with 2 nL of 0.3 mM
(0.6 pmol) anti-sense morpholino per protocols for each
of three separate experiments as described previously [11].
Morpholinos were designed to target the zebrafish
ortholog to a G-protein coupled receptor the loss of func-
tion of which has previously been shown to result in a
decrease in fat in C. elegans screen [12]. The C. elegans
GenePair corresponds to locus tag H09F14.1. The
zebrafish ortholog corresponds to mRNA [accession
XM_001340648], which is GPR142a. A morpholino with
sequence CGGGCGTCGTGCCATTGTGCCAGTC was
used to target the GPR142a mRNA. As a negative control,
three unrelated morpholinos were injected targeting the
ortholog to B3 (TATACGAAAATGAGCGACCGTGTTG)
and heat shock protein. From 3 to 7 dpf zebrafish larvae
were incubated with daily refreshing of nile red before rel-
ative quantification by fluorescence microscopy.
Results
Nile Red Can Penetrate the Deep Tissues of 7 dpf 
Zebrafish Larvae to Produce a Specific Fluorescent Signal 
Restricted to Lipid Rich Tissues Without Exerting Toxic 
Effects
Early development of the zebrafish proceeds quickly to
insure greater chance for survival in nature. By just 3 dpf
the protruding mouth has been formed. Thus oral delivery
of small molecules can be taken into consideration by this
stage of development. At 3 dpf zebrafish siblings generally
have equivalent amounts of lipid content, thus providing
a good baseline for quantifying subsequent changes in
lipid metabolism. Volume measurements reveal that over
50% of the volume of the yolk sac is depleted for develop-
ment from 4 to 7 dpf (Fig 1A. [13]). For these reasons we
believe this developmental time window is particularly
ideal for providing a potentially sensitive read out of fat
metabolic activity identify molecular activities regulating
vertebrate animal fat metabolism.
To establish the staining protocol, a 10 fold series of con-
centrations of nile red were tested starting from the estab-
lished concentration used previously in C. elegans genetic
screens [12]. A concentration of 10 ng/mL final nile red
concentration was ideal for obtaining a signal signifi-
cantly greater than background yet not present through-
out the entire embryo. The bulk of signal was restricted to
the lipid rich yolk sac (Fig. 1B). No overt nile red associ-
ated toxicity or effects on viability were observed in
zebrafish. Groups of 6 dpf zebrafish were incubated with
nile red for times ranging from 30 min to overnight. We
determined that at least 8 hours were needed to detect sig-
nal in the deeper regions throughout the embryo.
Pharmacological Targeting of PPARγ, SIRT-1, beta-
adrenergic receptors, and GPR109a is Generally Nutrition & Metabolism 2008, 5:23 http://www.nutritionandmetabolism.com/content/5/1/23
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A large portion of the yolk sac is absorbed during this sensitive developmental time window used to detect small molecule- mediated changes in fat metabolism (A) Figure 1
A large portion of the yolk sac is absorbed during this sensitive developmental time window used to detect 
small molecule-mediated changes in fat metabolism (A). Extended incubation at 5 ng/mL nile red provides ideal signal 
to noise ratio for detection of anatomically localized fat stores (B). Overnight incubation was even better with the signal in the 
gall bladder often disappearing (shown in Fig. 4).Nutrition & Metabolism 2008, 5:23 http://www.nutritionandmetabolism.com/content/5/1/23
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Evolutionarily Conserved from 7 dpf Zebrafish Larvae to 
Man
To be of greatest clinical relevance the zebrafish animal
model should be responsive to known mammalian phar-
macology regulating fat metabolism where both increases
or decreases in fat content should be detectable under the
assay conditions. To examine zebrafish pharmacology
and assay sensitivity, we targeted PPARγ or the hormone
responsive lipase (Fig. 2). Then total fat, total cholesterol
and gene expression of markers of differentiation were
quantified.
Insulin is the most potent known physiological inhibitor
of lipolysis, while nicotinic acid is a potent pharmacolog-
ical inhibitor of lipolysis [14]. Treatment of zebrafish lar-
vae from 3 to 7 dpf with 100 μM nicotinic acid but not
nicotinamide resulted in detectable increases in total fat,
whereas treatment with 100 μM resveratrol caused signif-
icant decreases in detectable fat (Fig. 3A). This decrease in
fat was even further decreased when resveratrol was sup-
plemented with 20 μM norepinephrine consistent with
previous results performed using murine adipocytes [15].
Treatment with 1 mM nicotinic acid from 3 to 10 dpf also
caused a significant 24% decrease in total cholesterol
from 42 ng cholesterol per mg protein to 32 ng/mg (Fig.
3B). Nicotinamide did not significantly alter the total cho-
lesterol (46 ng/mg). These results are consistent with the
long known ability of nicotinic acid but not nicotinamide
to decrease total cholesterol in the clinic.
Even though nicotinic acid has been used in the clinic for
over 50 years to treat high cholesterol, it was only recently
that the nicotinic acid G-protein coupled receptor was
identified [16], thus elucidating a critical link in the mech-
anism of action for one of the most effective drugs known
to prevent cardiac mortality [17]. This receptor has also
been identified as a gene up-regulated in response to
hypoxia or interferon gamma treatment in macrophages
[18]. The closely related molecule nicotinamide, does not
bind to the high affinity nicotinic acid receptor with any
appreciable affinity, but like nicotinic acid it does provide
NAD (Fig. 2). Thus nicotinamide is a negative control for
nicotinic acid signal transduction through the high affin-
ity nicotinic acid G-PCR GPR109a. Nicotinic acid treat-
ment to activate GPR109a caused the total fat content of
zebrafish larvae to increase, while nicotinamide did not
exert any dramatic change in total fat content (Fig. 3A).
Pathways regulating PPARγ-mediated adipocyte differentiation are shown on the left, while G-PCR targeted pathways working  via cAMP-mediated signal transduction to regulate lipolysis are shown on the right Figure 2
Pathways regulating PPARγ-mediated adipocyte differentiation are shown on the left, while G-PCR targeted 
pathways working via cAMP-mediated signal transduction to regulate lipolysis are shown on the right. The phar-
macologically targeted G-PCRs involved in lipolysis are GPR109a/HM74a or beta-adrenergic receptors. Nicotinic acid similarly 
affects both processes, inhibiting lipolysis and promoting adipocyte differentiation through PPARγ activation. However, nico-
tinic acid is also a precursor to NAD, which exerts the opposite effect (left). Resveratrol can both directly inhibit fatty acid syn-
thase and cause activation of SIRT-1 activity, both of which are known to decrease fat content in adipocytes. Vaticanol B is an 
only just recently characterized tropical tree bark-derived resveratrol tetramer determined to have much greater anti-inflam-
matory activity than resveratrol. Thus, we predict that Vaticanol B may be similarly involved in controlling fat metabolism.Nutrition & Metabolism 2008, 5:23 http://www.nutritionandmetabolism.com/content/5/1/23
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Thus, nicotinic acid responsive anti-lipolytic activity is
present in 6 dpf zebrafish similar to mammals.
Since the high affinity nicotinic acid G-protein coupled
receptor is of such great clinical significance we examined
the transcriptional regulation of GPR109a/HM74a after
nicotinic acid treatment and hypoxic stress by quantitative
RT-PCR. Hypoxic stress applied to 6 dpf zebrafish larvae
caused induction of GPR109a transcription (Fig. 3B) con-
sistent with previous observations linking hypoxia medi-
ated up-regulation GPR109a in monocytes [18].
Treatment with nicotinic acid by itself caused an increase
in GPR109a transcription that was synergistically
enhanced by hypoxia treatment, thus suggesting a positive
feedback loop (Fig. 3C).
To determine whether zebrafish PPARγ is responsive to
classical PPARγ activators, we exposed 6 dpf zebrafish to
20 nM 15d-PGJ2 overnight. The prostaglandin 15d-PGJ2 is
the most potent known endogenous activator of PPARγ.
Adipocyte fatty acid-binding protein (FABP4) and CD36
are classic PPARγ target genes in mammals [19]. Treat-
ment of zebrafish larvae with 15d-PGJ2 overnight caused
a greater than 10 fold increase in the amount of FABP4
and CD36 transcripts in zebrafish similar to what has
been observed in mammals (Fig. 3D). Nicotinic acid acti-
vation of GPR109a leads to localized endogenous 15d-
PGJ2 biosynthesis at professional antigen presenting cells
(Langerhans dendritic cells and macrophages, of which
there are many in 6 dpf zebrafish larvae), which similarly
activates PPARγ [18] leading to increased transcription of
Zebrafish respond to mammalian regulators of fat metabolism in an evolutionarily conserved manner Figure 3
Zebrafish respond to mammalian regulators of fat metabolism in an evolutionarily conserved manner. Similar 
to pharmacological application of niacin in the clinic, nicotinic acid inhibits zebrafish lipolysis (A), decreases total cholesterol 
(B), and increases expression of the most potent quantitative scavenger of oxidized lipids, CD36 and the classic marker of adi-
pocyte differentiation, FABP4 (D). Zebrafish larvae were exposed to nicotinic acid (NA), nicotinamide (NAM), resveratrol (R), 
or resveratrol with norepinephrine (NE) from 3–7 dpf before extraction of total phospholipids for quantitation by gas chroma-
tography (A) or quantitation of transcript levels (C and D). For cholesterol measurements zebrafish were treated with 1 mM 
concentrations of NA or NAM from 3–10 dpf (B).Nutrition & Metabolism 2008, 5:23 http://www.nutritionandmetabolism.com/content/5/1/23
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FABP4 (also known as aP2) and CD36 target genes in
mammals (Fig. 2). Treatment of zebrafish with nicotinic
acid resulted in increased gene expression of FABP4 and
CD36, while treatment with the related NAD precursor
nicotinamide did not cause any appreciable change.
Together these results are consistent with a high degree of
evolutionary conservation in zebrafish related to mam-
mals for PPARγ (15d-PGJ2 and nicotinic acid), SIRT-1 (res-
veratrol), beta-adrenergic receptor (norepinephrine,
isoproterenol), or GPR109a (nicotinic acid but not nicoti-
namide) pharmacology as related to fat metabolism (Fig.
2).
Small Molecules Regulating Fat Metabolism are Visually 
Detectable in Live Zebrafish larvae
To determine whether we could visually detect both
increases and decreases in this whole animal assay of fat
metabolism we incubated zebrafish larvae in nile red con-
taining embryo media and captured fluorescence micros-
copy images at 7 dpf. Exposure time used for capturing all
images were normalized to that initially obtained by auto-
matic exposure of untreated stained solvent only zebrafish
larvae. For determining whether we could detect pharma-
cological decreases in fat we used activators of the beta-
adrenergic receptor (isoproterenol or noradrenaline) or
SIRT-1 (nicotinamide adenine dinucleotide, resveratrol,
or potentially Vaticanol B). To determine whether we
could visually detect increases in fat we used specific acti-
vators of PPARγ (the thiazolidinedione drug troglitazone
or 15d-PGJ2, Fig. 2). Resveratrol treatment resulted in
highly reproducibly detectable decreases in fat. Con-
versely, treatment with just 20 nM of the highly stable
PPARγ activator troglitazone resulted in visually detecta-
ble increases in fat (Fig. 4 and 5). Treatment with the SIRT-
1 inhibitor sirtinol was less consistent in results due to
poor solubility combined with randomness of larval
movement activity. Nonetheless, some fish did exhibit
increased detectable fat.
Several tetramers of resveratrol derived from acetone
extracts of tree bark have garnered increased attention
owing to their ability to inhibit the map kinase pathway
and thus suppress cancer cell line growth. Vaticanol B in
particular was distinctively more active than resveratrol in
its ability to inhibit LPS-mediated production of nitric
oxide, TNFα, and PGE2 [20]. However, it is not known
how this compound affects fat metabolism. Thus we
examined fat metabolism using the zebrafish larvae nile
Pharmacology causing decreases or increases in fat metabolism is visually detectable in a quantitative fashion by using live  zebrafish nile red fluorescence microscopy Figure 4
Pharmacology causing decreases or increases in fat metabolism is visually detectable in a quantitative fashion 
by using live zebrafish nile red fluorescence microscopy. Zebrafish were incubated with daily refreshing of fish water 
containing nile red with or without 100 μM resveratrol (R) or 10 nM troglitazone (TZD). Exposure time for all fluorescent 
images was set to that of untreated zebrafish (left). Bright field images are provided to show lack of overt toxicity.Nutrition & Metabolism 2008, 5:23 http://www.nutritionandmetabolism.com/content/5/1/23
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Conservation of pharmacological pathways and consistency amongst groups of animals are shown Figure 5
Conservation of pharmacological pathways and consistency amongst groups of animals are shown. NAD or res-
veratrol is known to activate SIRT-1. Conversely, sirtinol is an inhibitor of SIRT-1. Vaticanol B (Vat B) is a resveratrol tetramer 
natural product predicted to activate SIRT-1 as well (A). Isoproterenol or norepinephrine activation of beta-adrenergic recep-
tors causes a decrease in detectable fat. Conversely, activation of PPARγ promotes adipocyte diferentation as predicted for 
treated zebrafish larvae. This slows the normal reduction in fat stores seen during this window of development.Nutrition & Metabolism 2008, 5:23 http://www.nutritionandmetabolism.com/content/5/1/23
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red fluorescence assay. Treatment of zebrafish with Vatica-
nol B revealed a fat reducing activity that was approxi-
mately equivalent in potency to that of resveratrol itself
(Fig. 4A). Targeting of the beta-adrenergic receptor with
norepinephrine or the more chemically stable molecule
isoproterenol also resulted in reproducibly detectable
decreases in fat content (Fig. 4B). All examined pharmaco-
logical data support the notion that signal transduction
regulating fat and cholesterol metabolism through beta-
adrenergic receptors, SIRT-1, and the high affinity nico-
tinic acid G-protein coupled receptor GPR109a are highly
evolutionarily conserved from fish to man. Significantly,
whole zebrafish nile red fluorescence microscopy also
enables examination of overt pharmacological toxicity.
Anti-sense knockdown of zebrafish ortholog to G-protein 
coupled receptor previously identified in C. elegans nile 
red fat metabolism screen, reveals that GPR142 may be a 
good target of future obesity drug development
Genetic screens have previously been used to identify 305
out of 16,757 screened genes the loss of function of which
results in decreased fat content in C. elegans [12]. From
this screen we selected two G-protein coupled receptors to
examine by anti-sense knockdown in zebrafish given their
drug accessibility. We limited our choices to G-PCRs since
they are the most commercially successful class of phar-
maceutical drug targets. One G-PCR was chosen because
the C. elegans loss of function results in increased fat con-
tent (C. elegans H09F14.1) while the other leads to
decreases in fat (C. elegans F56B6.5). Knockdown of the
zebrafish ortholog to C. elegans F56B6.5 resulted in devel-
opmental defects thus suggesting that complete antago-
nism of this GPCR may be toxic. Knockdown of H09F14.1
however, did cause detectable decreases in fat (Fig. 6). The
zebrafish gene corresponds to GPR142a. Thus GPR142a is
a candidate drug target for development of anti-obesity
therapeutics.
Conclusion
The zebrafish yolk sac is a finite maternally derived energy
source that predominately dwindles in size during the first
week of development (Fig. 1). In this study we determine
that the rate by which the zebrafish yolk sac diminishes is
predictably affected by small molecules known to regulate
mammalian fat metabolism via PPARγ adipogenic and
hormone sensitive lipolytic pathways (Fig. 2 and 3). Both
direct (15d-PGJ2) and indirect (nicotinic acid) PPARγ ago-
nists caused increased FABP4 and CD36 gene expression
in 7 dpf zebrafish larvae (Figure 3D). Conversely, beta-
adrenergic agonist exposure (norepinephrine or isoproter-
enol) led to decreases in detectable fat in zebrafish larvae
(Fig. 3A and 5B).
Our examination of nicotinic acid pharmacology in
zebrafish larvae also supports a high degree of evolution-
ary conservation for GPR109a signaling. Nicotinic acid
functions as a potent inhibitor of adipocyte lipolysis by
signaling through the high affinity nicotinic acid G-pro-
Antagonists of GPR142 are candidate future obesity drugs Figure 6
Antagonists of GPR142 are candidate future obesity drugs. Anti-sense knockdown of G-protein coupled receptor 
gene products the loss of function previously determined to cause decrease in fat content [12]. Incubation with the stable beta-
adrenergic agonist isoproterenol is shown as a positive control causing increased lipolysis for comparison.Nutrition & Metabolism 2008, 5:23 http://www.nutritionandmetabolism.com/content/5/1/23
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tein coupled receptor GPR109a. This causes Gi-coupled
decreases in cyclic AMP Protein kinase A, which inhibits
hormone sensitive lipase (Fig. 2[14,16]). Accordingly,
zebrafish larvae exposed to nicotinic acid from 3 to 7 dpf
have resultant increases in total fat (Fig. 3A). Zebrafish
exposed to nicotinic acid from 3 to 10 dpf dramatically
decreased (24% less, Fig. 3B) levels of total cholesterol
roughly similar to that observed for patients treated for
dyslipidemia with pharmacological niacin administra-
tion, which typically results in a decrease in total choles-
terol of 4–16% [21]. This result supports that this window
of zebrafish development is particularly sensitive to effec-
tors of cholesterol metabolism and that zebrafish may be
useful for the development of potential drugs to treat dys-
lipidemia that work through GPR109a.
While changes in fat content are visually quantifiable
under these in situ whole zebrafish larvae conditions, this
assay is limited by drug delivery. Our experiments using
the only OTC anti-obesity drug Orlistat (also known as
Alli or Xenical) failed to detect changes in zebrafish larvae
fat content due to water insolubility (unpublished obser-
vations). For testing molecules with poor solubility in
zebrafish it is necessary to inject them. This makes the
zebrafish assay not as high throughput, but it does work
and an examination of the logP of octanol:water parti-
tioning can generally predict whether injection will be
necessary [22].
Of all the molecules tested here, we see the most consist-
ently dramatic effects in reducing nile red detectable fat
after treatment with 100 μM resveratrol (Fig. 5). Resvera-
trol has been shown to increase mitochondrial biogenesis
and to shift the health of mice fed high calorie diets to that
of mice fed standard diets, significantly increasing their
lifespan and motor function [23]. Resveratrol can also
function as a direct inhibitor of fatty acid synthase [24].
Thus resveratrol is being considered for the clinical treat-
ment of obesity. Given that fat reduction is known to
extend lifespan in mice [25], these studies provided a
potential mechanistic explanation for resveratrol-medi-
ated increases in lifespan observed in every model organ-
ism tested to date.
Newly discovered pathways are now being targeted for
therapeutic clinical obesity drug development. Knock-
down of zebrafish GPR142a causes a significant decrease
in detectable fat without causing overt developmental
defects (Fig. 6), thus supporting the notion that this may
be a good target for the development of anti-obesity drugs
(Fig. 6). Little is known regarding GPR142. The first pub-
lished report of GPR142 based purely on genomic
sequence mentioned its presence in zebrafish. GPR142 is
expressed throughout the brain as well as spleen, liver,
kidney, and testes [26]. No examination of adipose tissue
expression has been reported to date. GPR142 is an
orphan G-PCR – neither endogenous nor xenobiotic lig-
ands are known. Given the high level of GPR142 expres-
sion in so many tissues and its drug accessibility as
receptor, this would appear to be an ideal anti-obesity
drug target. More GPR142 research is needed to determine
whether it is expressed in adipose tissue and what the
effect of GPR142 antagonism may have on fat content in
mammals along with possible toxicity.
While it was commonly believed that hormone sensitive
lipase is the rate-limiting enzyme in lipolysis, the recent
discovery of triglyceride lipases revealed a more complex
picture [27]. Hormone sensitive lipase turns out to be the
major lipase for catecholamine and natriuretic peptide-
stimulated lipolysis, whereas adipose triglyceride lipase
mediates basal triglyceride lipolysis [28]. What more this
basic mechanism of lipolysis involving triglyceride lipase
followed by hormone sensitive lipase and lastly
monoglyceride lipase is conserved from yeast to man but
is poorly understood [29].
Our experiments reveal for the first time that the direct
addition of NAD causes a decrease in total fat content (Fig.
5A). These results are consistent with observations of the
CD38 knockout mouse, which leads to a five-fold increase
in NAD levels that results in prevention of high fat diet
induced obesity through increased metabolic activity
[30]. Along these lines, drugs targeting CD38 inhibition
or NAD supplementation are only just recently being con-
sidered in obesity research. In one of the few examples
examining the direct application NAD to an animal, intra-
nasal administration of NAD was determined to confer
great protection from transient focal ischemia in rats. This
was quantified by infarct size measured in the brain hem-
isphere respectively connected with the given nostril
where the negative control was the untreated opposite
hemisphere [31]. The whole zebrafish nile red fluores-
cence fat metabolism assay can help narrow the list of
potential future drug targets for treating clinical obesity.
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